Title
California Family Planning Health Care Providers' Challenges to Same-Day Long-Acting Reversible Contraception Provision EDITORIAL COMMENT

Permalink
https://escholarship.org/uc/item/3vq179t1

Journal
OBSTETRICAL & GYNECOLOGICAL SURVEY, 71(5)

ISSN
0029-7828

Authors
Biggs, MA
Harper, CC
Brindis, CD

Publication Date
2016-05-01

Peer reviewed
OBJECTIVE: To assess the extent to which practices offering family planning services are able to offer intrauterine devices (IUDs) and implants in one visit and to identify the reasons why multiple visits may be required.

METHODS: In the fall of 2011, 1,000 California family planning providers were asked about their long-acting reversible contraception delivery practices in a probability survey. We used multivariable logistic regression to examine practice characteristics associated with same-day provision of IUDs and implants.

RESULTS: Among the 636 responding practices, 67% offered an IUD and 40% offered a contraceptive implant onsite. Among those with onsite provision, the majority required two or more visits to place an IUD (59%); almost half required two visits to place an implant (47%). Nearly all Planned Parenthood practices could place an IUD (95%) or implant (95%) at the initial visit, whereas the majority of all other practice types could not. The main reasons for delaying IUD and contraceptive implant provision included the need to screen and wait for test results (68% and 24%, respectively) and clinic flow and scheduling issues (50% and 64%, respectively). Multivariable analyses indicated that Planned Parenthood practices were significantly more likely than private practices to have same-day insertion protocols.

CONCLUSION: Most of the family planning providers surveyed have not adopted same-day long-acting reversible contraception insertion protocols and face barriers to same-day provision.

(Obstet Gynecol 2015;0:1–8)
DOI: 10.1097/AOG.0000000000000969

LEVEL OF EVIDENCE: III

Long-acting reversible contraception (LARC), which includes intrauterine devices (IUDs) and the single-rod contraceptive implant, are highly effective and acceptable to women who use them. Although use of these methods in the United States has increased, it still remains substantially lower than less effective methods such as pills or condoms. The American College of Obstetricians and Gynecologists recommends same-day IUD and implant placement protocols to reduce barriers to use and specifies that immediate insertion postpartum, postabortion, and after miscarriage is safe, appropriate, and necessary to reduce delays. Although pregnancy must be ruled out before placement, screening for sexually transmitted infections (STIs) is not required unless the woman presents with risk factors such as age 25 years or younger or multiple male partners. An asymptomatic woman with risk factors should be tested and the IUD can be inserted that same day. If a woman is symptomatic, she should be treated and return later to have the IUD inserted. The evidence indicates that there is no increased risk of pelvic inflammatory disease with same-day IUD placement. Same-day insertion protocols lessen patient burden, costs associated with additional visits, and the risk of experiencing an unintended pregnancy between the initial and subsequent visit.
Despite existing support for same-day placement protocols, there are few studies documenting the extent to which health care providers offer IUDs and implants in one visit or the reasons why multiple visits are needed. The limited available research indicates that few health care providers use single-visit insertion protocols. In a national survey, 13% of obstetrician–gynecologists reported that they offered IUDs in a single visit.12 Similarly, data from family planning clinic directors in Colorado and Iowa indicated that a small minority of agencies typically offered IUDs (18%) or implants (36%) in one visit. Multiple visits were mostly required to conduct screening tests and for patient decision-making.13 In 2006, health care providers enrolled in California’s family planning program, Family Planning, Access, Care, and Treatment (PACT), were surveyed; 7% offered an IUD in one visit.14,15 Since then, trainings have been conducted to encourage Family PACT health care providers to update IUD practices,16 and the single-rod contraceptive implant which was introduced to the U.S. market in 2006, was added to the Family PACT formulary in 2007. This study aims to assess whether the proportion of Family PACT practices able to offer single visits for LARC has changed over time and to identify the reasons why practices may need multiple visits. Family PACT practice sites represent a wide range of practices such as private practice physicians, community health centers, and Planned Parenthood centers, enabling the identification of the types of practices that may face the greatest barriers to same-day LARC provision.

MATERIALS AND METHODS

The California Family PACT program offers comprehensive family planning services and includes provision of all contraceptive methods approved by the U.S. Food and Drug Administration, including IUDs and implants, at no cost to the patient. Family PACT health care providers can be reimbursed for all contraceptive methods, pregnancy testing, STI screening, and education and counseling. In Fiscal Year 2009–2010, 2,168 health care providers were enrolled in the Family PACT program. A Family PACT provider typically represents a practice site where Family PACT services are delivered such as a solo or group practice or community health center. In September 2011, 1,000 Family PACT practice sites were mailed a survey to be completed by the site’s medical director or other senior clinician or staff responsible for overseeing family planning services at the practice site. Probability proportional to size sampling strategy was utilized to select participating sites. In this strategy, sites serving a greater number of patients have a greater probability of being selected. The survey instrument included questions about the practice setting, placement protocols, and barriers to IUD and implant provision. Survey items were based on prior LARC research.14,16 Before the initial mailing,
a separate letter from the California Office of Family Planning, the program's administrator, was sent to all sampled Family PACT practices requesting their participation as part of program requirements. Respondents were instructed to complete and return the survey by mail using a self-addressed envelope or to complete an identical survey online. A square of chocolate was included inside the survey package to serve as a token upfront incentive for completing the survey. All non-responding sites were sent up to three follow-up reminder paper mailings; additionally, those with e-mail addresses (659 practices) were sent weekly

Table 2. Reasons Patients Must Have More Than One Visit to Get Long-Acting Reversible Contraception Among Practices Offering These Methods Onsite

<table>
<thead>
<tr>
<th>Reason</th>
<th>Hormonal or Copper IUD n (%)</th>
<th>95% CI</th>
<th>Contraceptive Implant n (%)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>239 (100)</td>
<td></td>
<td>103 (100)</td>
<td></td>
</tr>
<tr>
<td>Reasons more than one visit needed to get</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening tests or wait for test results</td>
<td>163 (68)</td>
<td>62–74</td>
<td>25 (24)</td>
<td>17–34</td>
</tr>
<tr>
<td>Clinic flow, scheduling issues, or few clinicians</td>
<td>120 (50)</td>
<td>44–57</td>
<td>64 (64)</td>
<td>61–80</td>
</tr>
<tr>
<td>Need to order the method</td>
<td>69 (29)</td>
<td>23–34</td>
<td>30 (29)</td>
<td>21–39</td>
</tr>
<tr>
<td>Desire to reduce the time burden on the patient</td>
<td>22 (9)</td>
<td>5–14</td>
<td>8 (8)</td>
<td>4–15</td>
</tr>
<tr>
<td>Need time for patient education and counseling</td>
<td>19 (8)</td>
<td>5–12</td>
<td>14 (14)</td>
<td>8–22</td>
</tr>
<tr>
<td>Must wait for menses</td>
<td>11 (5)</td>
<td>3–8</td>
<td>8 (8)</td>
<td>4–15</td>
</tr>
<tr>
<td>Billing or insurance issues</td>
<td>7 (3)</td>
<td>1–6</td>
<td>2 (2)</td>
<td>0.5–8</td>
</tr>
<tr>
<td>Need to allow time for patient consent</td>
<td>6 (3)</td>
<td>1–6</td>
<td>5 (4)</td>
<td>1–9</td>
</tr>
</tbody>
</table>

IUD, intrauterine device; CI, confidence interval.
Respondents could check more than one response. Includes only practices who offer each method onsite and require more than one visit for placement.

Table 3. Practice Characteristics Associated With Not Requiring Sexually Transmitted Infection Tests Before Long-Acting Reversible Contraception Placement Among Practices Offering These Methods Onsite: Bivariable Logistic Regression Results

<table>
<thead>
<tr>
<th>Practice Characteristics</th>
<th>IUDs (n=410)</th>
<th>Implants (n=223)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practice Does Not Require STI Tests Before Placing</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Practice type</strong></td>
<td>n (%)</td>
<td>OR [95% CI]</td>
</tr>
<tr>
<td>Total</td>
<td>148 (36)</td>
<td></td>
</tr>
<tr>
<td>Practice type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private practice (reference)</td>
<td>18 (13)</td>
<td>31 (78)</td>
</tr>
<tr>
<td>Community health center</td>
<td>36 (25)</td>
<td>2.21 [1.83–4.11]</td>
</tr>
<tr>
<td>Planned Parenthood</td>
<td>75 (87)</td>
<td>44.70 [20.00–90.87]</td>
</tr>
<tr>
<td>Other</td>
<td>19 (42)</td>
<td>4.79 [2.21–10.37]</td>
</tr>
<tr>
<td>Number of visits to insert LARC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hormonal or copper IUD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Two or more visits (reference)</td>
<td>33 (14)</td>
<td>75 (82)</td>
</tr>
<tr>
<td>Implant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One visit</td>
<td>93 (74)</td>
<td>9.47 [5.25–17.08]</td>
</tr>
<tr>
<td>Two or more visits (reference)</td>
<td>27 (23)</td>
<td>86 (84)</td>
</tr>
<tr>
<td>Practice specialty</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary care or multispecialty (reference)</td>
<td>47 (24)</td>
<td>44 (85)</td>
</tr>
<tr>
<td>Family planning</td>
<td>63 (73)</td>
<td>8.92 [5.00–15.90]</td>
</tr>
<tr>
<td>Obstetrics and gynecology or women's health</td>
<td>38 (31)</td>
<td>1.44 [0.87–2.38]</td>
</tr>
</tbody>
</table>

STI, sexually transmitted infection; IUDs, intrauterine devices; OR, odds ratio; CI, confidence interval; LARC, long-acting reversible contraception.
* P<.05.
follow-up e-mails to encourage a good response rate. Six weeks after the survey launch, medical directors from nonresponding sites were telephoned to request participation. When multiple surveys (n = 11) were received from the same practice, one survey from each site was randomly selected to be included in the final sample. Six percent (61 of 1,000) of sites were found to be invalid as a result of clinic closings, incorrect addresses, and disenrollment, leaving a final sample of 939 eligible sites. Study details have been described elsewhere.17 This study received ethical approval from the University of California, San Francisco, Committee on Human Research.

The outcome variables included whether a practice offered same-day placement of the hormonal or copper T IUD or contraceptive implant and whether tests to screen for STIs were required before IUD and implant provision.

Respondents were asked whether their practice offered the hormonal IUD (Mirena), copper T IUD (ParaGard), or contraceptive implant (Implanon) onsite or by referral or neither onsite or by referral. At the time of the study, the hormonal IUDs, Skyla and Liletta, and the contraceptive implant, Nexplanon, had not yet been introduced to the U.S. market. Those indicating that their practice offered IUDs or implants onsite were asked, “In your practice, can a client interested in getting any of the following methods have the procedure done on the same day she asks for it? (Count all visits for counseling, assessment and the procedure.)” Respondents were directed to respond for each method. We created a variable for number of visits needed as well as a dichotomous variable for same-day provision. Respondents who indicated more than one visit was needed for placement were asked to indicate the reasons for each method by checking options from a list of five options (must wait for test results, clinic flow, scheduling issues, few clinicians, and the need to order the method). Write-in responses were recoded into the original or new categories.

Respondents offering IUDs or contraceptive implants onsite were asked whether their practice required STI tests before placing the method (yes or no).

The survey instrument included questions regarding respondents’ professional position, practice type, and practice specialty.

 Frequencies are presented for practice characteristics and outcome variables. We used bivariable analyses to model the dichotomous outcomes of STI tests required for IUD or implant provision and same-day IUD or implant provision using logistic regression. We then assessed multivariable associations between practice characteristics and same-day IUD or implant placement. Many sites surveyed were not independent because they were part of a larger agency, for example, a county health department, community clinic, or Planned Parenthood affiliate. Therefore, generalized estimating equation models were used to account for clustering by the 471 agencies in the bivariable and multivariable analyses. All analyses were conducted in STATA 13.1. Significance was reported at P ≤ .05.

RESULTS

The survey had a response rate of 68% (636 of the 939 eligible sites). Respondent and practice characteristics are presented in Table 1. Over half of respondents held the position of medical director (58%, n = 367), 5% (n = 34) were department chiefs, 9% (n = 55) were other physicians, and over one-fourth (28%, n = 180) were clinic managers or other clinic staff. Nearly half of respondents represented solo and group private practices (46%, n = 291), over one-fourth (28%, n = 180) community health center practices, 14% (n = 89) Planned Parenthood practices, and 13% (n = 80) other practice types such as county or city health departments, hospital-based outpatient clinics, and school-based health centers. Approximately one-fourth (26%) of respondents represented obstetrics and gynecology and women’s health specialties, 16% represented family planning specialties, and 58% represented primary care or multispecialty practices including general, internal, family, and adolescent medicine and school health (primary care or multispecialty).

Sixty-seven percent of practices provided a form of IUD onsite and 40% the implant. Approximately 41% of practices providing IUDs onsite offered same-day placement for the IUD; over half (53%) of those providing implants onsite offered same-day service. Results for same-day provision of the hormonal and copper IUD were so similar that these were combined in all subsequent analyses.

The recoding of open-ended responses regarding the reasons why multiple visits are required generated four new categories of reasons as listed in Table 2. Among practices who offered the IUD onsite, the most common reasons for multiple visits were a perceived need for screening tests and to wait for test results (68%) followed by clinic flow, scheduling issues, few clinicians (50%), and the need to order the method (29%) (Table 2). Among practices offering the contraceptive implant onsite, clinic flow or scheduling issues and few clinicians were the primary (64%)
reasons for needing multiple visits for placement, followed by the need to order the method (29%) and screening tests (24%).

Table 3 shows that 36% of practices offering IUDs onsite and 90% offering implants do not require STI testing before placement. According to bivariable analyses, the practices most likely to require STI tests before IUD or implant provision included private practices and primary care or multispecialty practices. Sites requiring two or more visits for IUD and implant placement were significantly more likely to require STI testing before placement.

Multivariable generalized estimating equation results showed that Planned Parenthood practices were significantly more likely than private practices to offer same-day IUD placement (adjusted odds ratio [OR] 23.41, 95% confidence interval [CI] 7.37–74.34) (Table 4). The unusually high ORs for Planned Parenthood sites is the result of the limited variability among this group with nearly all requiring no more than one visit for IUD placement. Nearly all Planned Parenthood practices could place an IUD (95%) or implant (95%) at the initial visit, whereas the majority of all other practice types could not (Table 4). Requiring STI testing before IUD placement was significantly associated with a reduced odds of single-visit IUD placement (adjusted OR 0.19, CI 0.11–0.35).

Results of the multivariable generalized estimating equation model predicting single-visit implant placement indicated that Planned Parenthood (adjusted OR 25.19, CI 7.82–81.17) and other practice types (adjusted OR 3.41, CI 1.07–10.86) were significantly more likely than private practices to offer same-day placement. No other variables were significantly associated with number of visits to place the implant.

DISCUSSION

The California practices surveyed comprise a diverse sample of sites enrolled in a program, which allows them to offer all contraceptives, including IUDs and implants, at no cost to their Family PACT patients, eliminating a barrier that is often insurmountable in other contexts.18,19 As a whole, the program has observed a steady increase in IUD and implant provision.20

Our findings demonstrate that 41% of the California practices that provide IUDs can offer same-day placement, which is substantially higher than the 7% reported in 2006 among a similar sample14 and higher than the 13% reported more recently among a national sample of obstetrician–gynecologists,12 suggesting improvements in health care provider capacity. This change in the ability to offer IUDs in one visit may be a result of new professional guidelines recommending same-day IUD provision21 in conjunction with health care providers’ more favorable views about IUDs.12,22

However, significant obstacles to same-day provision still exist. Same-day provision was not an option for the large number of practices that did not offer these methods onsite. Thus, for many women, their visit to a LARC-offering provider may already represent their second visit, after a referral. Among health care
providers offering LARC methods onsite, the need to order devices was a barrier to same-day placement. The cost of keeping IUDs in stock may become more feasible with the recent introduction of a low-cost device. Training family planning health care providers to offer the full range of contraceptive options and to forecast patient demand to better stock devices and how to obtain devices at reduced cost through a 340B program or group purchasing organization would help further reduce barriers to method provision and ensure choice in method.

Despite professional guidelines stating that STI screening should not delay IUD placement, most respondents, in particular community health center and private practice respondents, required STI testing results before placing IUDs and cited it as the primary reason for delay. Although delayed IUD insertion is necessary for active infections, the screening test itself should not delay insertion. The large proportion of practices requiring STI tests before IUD placement may be indicative of health care provider concerns about increasing patients' STI risk with IUD placement, a concern that has been found in other studies.

There has been very little research examining the extent to which health care providers can offer the contraceptive implant in one visit. Similar to what has been reported in Colorado and Iowa, a little over half of California practices offering the contraceptive implant onsite reported that they have same-day visit implant placement capacity. Clinic flow and scheduling issues were the main reasons respondents gave for requiring multiple visits. The Centers for Disease Control and Prevention Medical Eligibility Criteria for Contraceptive Use places no restriction for implant placement among women at risk or with an STI and states that STI screening tests are not required before implant placement.

The capacity to offer same-day IUD or implant placements was strongly associated with practice type. Practices that specialize in family planning and women’s health were more likely to offer IUDs and implants onsite and on the same day. These practices may have been better equipped to offer same-day provision because of greater availability of devices and trained clinicians, and they may see more patients who have already decided on the IUD or implant before their visit. They may also have the staffing necessary to allow for greater flexibility in terms of clinic flow. Primary care and multispecialty practices faced the greatest challenges to same-day provision. Practices that focus on a broader range of health conditions may need to integrate family planning counseling and placement within a primary care visit and may lack clinicians trained to place IUDs and implants. Future studies identifying approaches used by practices that have been successful in implementing same-day insertion protocols could be used to develop and implement strategies among those health care providers facing the greatest challenges.

Qualitative interviews with clinicians and health educators have suggested that the primary barriers to immediate LARC provision include cost, scheduling issues, and lack of trained health care providers. Although the cost of the device is not a barrier for Family PACT patients, it can be a barrier to provision for health care providers. The high upfront costs to keep devices in stock can make it difficult to have the method on hand when a patient requests it, thereby contributing to the reasons for delayed placement. Whether certain visit protocols are incentivized by

<table>
<thead>
<tr>
<th>n (%)</th>
<th>OR [95% CI]</th>
<th>Adjusted OR [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>118 (53)</td>
<td>0.23 [0.08–0.65] *</td>
<td>0.62 [0.19–1.95]</td>
</tr>
<tr>
<td>110 (56)</td>
<td>1.57 [0.62–3.96]</td>
<td>2.02 [0.71–5.74]</td>
</tr>
<tr>
<td>8 (22)</td>
<td>66.16 [18.49–236.75] *</td>
<td>25.19 [7.82–81.17] *</td>
</tr>
<tr>
<td>73 (95)</td>
<td>3.00 [1.04–8.57] *</td>
<td>3.41 [1.07–10.86] *</td>
</tr>
<tr>
<td>31 (32)</td>
<td>5.01 [2.82–8.90] *</td>
<td>1.82 [0.79–4.13]</td>
</tr>
</tbody>
</table>
the added cost or added revenue they may provide
the practice should be further explored. Overcoming
these barriers will be critical to helping health care
providers develop the capacity to same-day LARC
provision.

This study has limitations. Our measure of health
care practices’ capacity for same-day placements is
likely higher than the actual proportion of women
with same-day placements. Better documentation of
the actual number of visits for an IUD or implant
placement would improve our understanding of the
barriers to provision and uptake. Another limitation is
that we did not ask respondents an open-ended ques-
tion as to their reasons for delay, but rather restricted
their responses to a researcher-generated list. Thus,
there may be additional reasons for delay that were
not captured by this study. Furthermore, the questions
posed to respondents may have been prone to a desir-
ability bias, potentially skewing same-day reports to
be more frequent than actual practice. Finally, our
results may not be generalizable to other practices
and states without a state Medicaid waiver, where
cost is an even more significant barrier to LARC
provision.

Although this study indicates that there has been
improvement in the number of practices able to offer
an IUD or implant the same day requested, still, many
women interested in an IUD or implant will likely
need to be referred elsewhere, endure unnecessary
screening tests, and asked to return at a later time to
have a method placed, causing some women to forgo
these methods.31

REFERENCES

1. Fleming KL, Sokoloff A, Rainie TR. Attitudes and beliefs about
the intrauterine device among teenagers and young women.
Contraception 2010;82:178–82.

2. Kittur ND, Secura GM, Peipert JF, Madden T, Finer LB,
Allsworth JE. Comparison of contraceptive use between the
Contraceptive CHOICE Project and state and national data.
Contraception 2011;83:479–85.

contraception use among U.S. women aged 15–44. NCHS Data Brief

4. Jones J, Mosher W, Daniels K. Current contraceptive use in
the United States, 2006–2010, and changes in patterns of use since

5. Committee on Adolescent Health Care Long-Acting Reversible
Contraception Working Group, The American College of Ob-
stetricians and Gynecologists. Adolescents and long-acting
reversible contraception: implants and intrauterine devices.
ACOG Committee Opinion No. 539. American College of

6. American College of Obstetricians and Gynecologists Commit-
tee on Gynecologic Practice; Long-Acting Reversible Contra-
ception Working Group. Increasing use of contraceptive
implants and intrauterine devices to reduce unintended preg-
nancy. ACOG Committee Opinion No. 450. American College
of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:
1434–8.

7. Sufrin CB, Averbach SH. Testing for sexually transmitted
infections at intrauterine device insertion: an evidence-based

8. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M,
Wendt JM, Steinauer JE. Neisseria gonorrhoea and Chlamydia
trachomatis screening at intrauterine device insertion and pelvic

Same-day intrauterine device placement is rarely complicated by

10. Wang NA, Papic M, Parisi SM, Baldauf E, Rapkin R,
Schwarz EB. Same-day placement of intrauterine contraception

11. Langston AM, Joslin-Rother SL, Westhoff CL. Immediate post-
abortion access to IUDs, implants and DMPA reduces repeat
pregnancy within 1 year in a New York City practice. Contra-
ception 2014;89:103–8.

12. Lucchowski AT, Anderson BL, Power ML, Raglan GB, Espey E,
Schulkin J. Obstetrician-gynecologists and contraception: long-
acting reversible contraception practices and education. Con-
traception 2014;89:578–83.

13. Biggs MA, Aroms A, Turner R, Brindis CD. Same-day LARC

14. Harper CC, Speidel JJ, Drey EA, Trussell J, Blum M,
Darney PD. Copper intrauterine device for emergency contra-
ception: clinical practice among contraceptive providers.

15. Harper CC, Blum M, Thiel de Bocanegra H, Darney PD,
to practice: the provision of intrauterine contraception. Obstet

16. Lewis C, Darney P, Thiel de Bocanegra H. Intrauterine contra-
ception: impact of provider training on participant knowledge

17. Biggs MA, Harper CC, Malvin J, Brindis CD. Factors influenc-
ing the provision of long-acting reversible contraception in

18. Pace LE, Dusetzina SB, Fendrick AM, Keating NL, Dalton VK.
The impact of out-of-pocket costs on the use of intrauterine
contraception among women with employer-sponsored insur-

19. Eisenberg D, McNicholas C, Peipert JF. Cost as a barrier to
long-acting reversible contraceptive (LARC) use in adolescents.

20. Bixby Center for Global Reproductive Health. Family PACT
of California, San Francisco; 2013.

21. Long-acting reversible contraception: implants and intrauterine
devices. ACOG Practice Bulletin No. 121. American College of

Long-acting reversible contraception for adolescents and young

23. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hills SD,
Marchbanks PA. Health care provider attitudes and practices
related to intrauterine devices for nulliparous women. Obstet

VOL. 0, NO. 0, MONTH 2015

Biggs et al. Challenges to Same-Day LARC Provision 7

25. Medicines 360. Actavis and Medicines360 announce FDA approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to three years. 2015.


